Serum sickness-like illness associated with rifampicin.
We describe a patient with human immunodeficiency virus infection who developed the main clinical features of a serum sickness reaction while receiving treatment with daily therapeutic doses of tuberculostatic drugs. A decrease in complement titers as well as a detection of significant levels of circulating immune complexes were observed. A positive skin test result was observed six hours after an intradermal test with rifampicin. No immunoglobulin or complement deposition was observed by direct immunofluorescence of a punch biopsy specimen from the cutaneous lesion.
Parra
F M
FM
Servicio de Alergia, Hospital Ramón y Cajal, Madrid, Spain.
Pérez Elias
M J
MJ
Cuevas
M
M
Ferreira
A
A
D000328:Adult; D000936:Antigen-Antibody Complex / Q000097:blood; D001706:Biopsy; D003165:Complement System Proteins / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008297:Male; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012713:Serum Sickness / Q000139:chemically induced*; D012867:Skin / Q000737:chemistry / Q000473:pathology
D000936:Antigen-Antibody Complex; D007136:Immunoglobulins; D003165:Complement System Proteins; D012293:Rifampin